AI assistant
Sending…
Marker Therapeutics, Inc. — Director's Dealing 2018
Dec 28, 2018
35150_dirs_2018-12-28_1c7ccc69-0bac-49a4-8373-50687f30433b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Marker Therapeutics, Inc. (MRKR)
CIK: 0001094038
Period of Report: 2018-12-21
Reporting Person: Moseley Ken (General Counsel)
More from Marker Therapeutics, Inc.
Interim / Quarterly Report
2026
May 15
Regulatory Filings
2026
Mar 20
Annual Report
2026
Mar 20
Proxy Solicitation & Information Statement
2026
Mar 20
Annual Report
2026
Mar 18
Regulatory Filings
2026
Feb 9
Director's Dealing
2025
Nov 19
Director's Dealing
2025
Nov 19
Director's Dealing
2025
Nov 19
Major Shareholding Notification
2025
Nov 17